Immuno-modulatory Progenitor Cell Migration and Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal stem cell therapies for tissue repair face challenges due to inefficient migration of MSC subtypes to target tissues, leading to high cell doses and off-target side effects, and difficulties in obtaining large quantities from bone marrow.
Innovation Solution
Identification and isolation of immuno-modulatory progenitor (IMP) cells expressing specific markers such as MIC A/B, CD304, CD178, CD289, CD363, CD99, CD181, EGF-R, CXCR2, and CD126, which can efficiently migrate to and repair damaged tissues through enhanced immuno-modulatory and paracrine signaling capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high cell doses of MSCs are used to ensure sufficient migration to target tissue, then tissue repair effectiveness is improved, but off-target side effects and volume-related side effects increase
Solution Approach 1:
The patent applies local quality by selecting and expanding specific MSC subpopulations (CD105+CD73+CD90+CD44+) with enhanced migratory properties. This creates a heterogeneous cell population with differentiated local qualities - some cells optimized for migration while others provide therapeutic functions, allowing effective tissue repair at lower doses without off-target effects
Solution Approach 2:
The patent changes the parameter of cell migratory capacity by culturing MSCs under specific conditions (serum-free medium, controlled oxygen tension, specific growth factors) that enhance the expression of migratory markers (CXCR4, CD44, VLA-4) and improve homing efficiency to target tissues, thereby reducing the required cell dose
2Quantity of substance
If large amounts of MSCs are obtained from bone marrow, then sufficient cell dose is achieved, but the difficulty of obtaining large quantities increases
Solution Approach 1:
The patent applies preliminary action by performing in vitro expansion of MSCs from small bone marrow samples before administration. The cells are cultured and multiplied under controlled conditions to achieve the required therapeutic dose, eliminating the need to harvest large quantities directly from the patient's bone marrow
Solution Approach 2:
The patent enables self-service by using the patient's own MSCs (autologous transplantation) that are expanded in vitro. The patient's cells serve their own therapeutic purpose, avoiding donor-to-donor variation and eliminating the need for complex donor screening and matching procedures
3Quantity of substance
If MSC subtypes with varying migration efficiency are used, then cell dose can be reduced, but the mixture includes cells that do not migrate efficiently to the tissue of interest
Solution Approach 1:
The patent applies segmentation by separating MSCs into distinct subpopulations based on surface marker expression (CD105, CD73, CD90, CD44) and migratory capacity. This creates a segmented cell therapy product where a specific fraction of highly migratory cells is enriched, ensuring both reduced total dose and improved population homogeneity for the migratory phenotype
Data Source
AI summary
The invention relates to immuno-modulatory progenitor (IMP) cells and their use in therapy.